TargetBeta
F3
coagulation factor III, tissue factor · also CD142, TF · CD molecules
6 programs in company-led studies act on F3, from 6 companies: 2 in phase 3, 1 approved with new studies. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (5 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| tisotumab vedotinrule | Pfizer | phase 4 | 112 running | – | NCIt |
| Anti-TF/TOP1i Antibody-drug Conjugate XNW28012rule | Evopoint Biosciences | phase 3 | 33 running | – | NCIt |
| Anti-TF Antibody-drug Conjugate MRG004Arule | Lepu Biopharma | phase 3 | 21 running | – | NCIt |
| SHR-4375 | Jiangsu HengRui Medicine | phase 2 | 22 running | – | the company's pipeline |
| Anti-TF/Exatecan Antibody-drug Conjugate STRO-004rule | Sutro Biopharma | phase 1 | 11 running | – | NCIt |
| Anti-TF/TOP1i Antibody-drug Conjugate XB371rule | Exelixis | phase 1 | 11 running | – | NCIt |
Conditions their studies are in
- Pancreatic Neoplasms, 2 programs
- Colorectal Neoplasms, 1 program
- Esophageal Neoplasms, 1 program
- Neoplasm Metastasis, 1 program
- Ovarian Neoplasms, 1 program
- Uterine Cervical Neoplasms, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Dec 31, 2026Anti-TF/TOP1i Antibody-drug Conjugate XNW28012 · Evopoint Biosciences · phase 3 · NCT06799637
- Jan 2027SHR-4375 · Jiangsu HengRui Medicine · phase 2 · NCT07298772
- Jun 2027Anti-TF Antibody-drug Conjugate MRG004A · Lepu Biopharma · phase 3 · NCT07138846
- Nov 30, 2027Anti-TF/TOP1i Antibody-drug Conjugate XB371 · Exelixis · phase 1 · NCT07123103
- Dec 2027Anti-TF/Exatecan Antibody-drug Conjugate STRO-004 · Sutro Biopharma · phase 1 · NCT07227168
- Dec 13, 2028tisotumab vedotin · Pfizer · phase 4 · NCT06952660
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.